Overexpression of CD44 is associated with a poor prognosis in grade II/III gliomas

被引：30

作者：

Hou, Chongxian ^{[1
]}

Ishi, Yukitomo ^{[1
]}

Motegi, Hiroaki ^{[1
]}

Okamoto, Michinari ^{[1
]}

Ou, Yafei ^{[2
]}

Chen, Jiawei ^{[3
]}

Yamaguchi, Shigeru ^{[1
]}

机构：

[1] Hokkaido Univ, Fac Med, Dept Neurosurg, Kita Ku, North 15 West 7, Sapporo, Hokkaido 0608638, Japan

[2] Hokkaido Univ, Grad Sch Informat Sci & Technol, Sapporo, Hokkaido 0600814, Japan

[3] Shantou Univ, Med Coll, Shantou 515041, Guangdong, Peoples R China

来源：

JOURNAL OF NEURO-ONCOLOGY | 2019年 / 145卷 / 02期

关键词：

CD44; Glioma; Prognostic factor; Biomarker; GLIOBLASTOMA-MULTIFORME; ADHESION MOLECULES; STEM-CELLS; EXPRESSION; HYALURONAN; INVASIVENESS; ACTIVATION; RESISTANCE; VARIANTS; CXCL12;

D O I：

10.1007/s11060-019-03288-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose Overexpression of CD44 has been detected in many types of tumor tissues. Moreover, CD44 is recognized as a cancer stem cell marker for many cancers. However, the prognostic value of CD44 for glioma patients has not yet been clarified. The authors tried to explore the impact of CD44 expression on grade II/III glioma patients. Methods To assess the RNA expression levels of CD44 in glioma tissues and normal brain tissues, meta-analyses were conducted in the online Oncomine database. The mRNA expression levels of CD44, CD44s, and CD44v2-v10 in 112 grade II/III glioma patients in Hokkaido University Hospital (HUH) were detected by qPCR. The RNA-seq data and clinical data of grade II/III glioma patients were obtained from The Cancer Genome Atlas (TCGA) and the Chinese Glioma Genome Atlas (CGGA) databases. Results Based on the Oncomine database, CD44 has significantly high expression in glioma tissues as compared with normal tissues. We explored the clinical relevance of CD44 mRNA expression based on the HUH cohorts, the TCGA cohorts, and the CGGA cohorts. In survival analysis, high mRNA expression of CD44 was correlated with poor overall survival and poor progression-free survival in grade II/III glioma patients. Multivariate Cox regression analyses confirmed CD44 as an independent prognostic factor for grade II/III glioma patients. Conclusions The present study suggests that overexpression of CD44 is associated with a poor prognosis for grade II/III glioma patients. Moreover, our findings suggest that CD44 could serve as a prognostic biomarker in grade II/III glioma patients.

引用

页码：201 / 210

页数：10

共 50 条

[1] TGF-β Receptor Inhibitors Target the CD44high/Id1high Glioma-Initiating Cell Population in Human Glioblastoma [J].